6[7]MANJ IHK,QU IROZ JA,SPORN J,et al.Enhancing neuronal plasticity and cellular resilience to develop novel,improved therapoutics for difficult to treat depression.Biol Psychiatry,2003,53 (8):707-742.
7[8]SANTARELL IL,SAXE MD.Substance P antagonists:meet the new drug,same as the old drugs? Insights from transgenic animal models.CNS Spectr,2003,8 (8):589 -596.
8[9]BUTTERWECK V,HEGGER M,W INTERHOFF H.Flavonoids of St.John's Wort reduce HPA axis function in the rat.Plants Med,2004,70(10):1008-1011.
9[10]O'BR IEN SM,SCOTT LV,D INAN TG.Cytokines:abnormalities in major depression and implications for pharmacological treatment.Hum Psychopharmacol,2004,19(6):397-403.
3Yamada M, Yasuhara H.Clinical pharmacology of MAO inhibitors: safety and future[J]. Neuroxicology, 2004 ;25( 1,2):215-271.
4O1ie JE Tonnoir B, Menard F, et al. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety[J]. Depress Anxiety. 2007;24(5):318-324.
5Rampello L, Chiechio S, Nicletti G, et al. Prediction of the response to citalopram and reboxetine in poststroke depressed patients[J]. Psychophamacology, 2004; 173(2):73-78.
6Zajecka JM, Albano D.SNRIs in the management of acqte major depressive disorder[J]. J Clic Psychinatry, 2004;65(Suppl 17):11-21.
7Lam RM, Kennedy SH. Evidence-based strategies for achieving and sustaining full remission in depression focus on Meta-analyses[J]. Can J Psychiatry, 2004;49(Suppl 1): 17-26.
8Sechter D, Vandel P, Weiller E, et al. A comparative study of milnacipran and paroxetine in outpatient with major depression[J]. J Affect Disord, 2004;83(2,3):233-236.
9Lynn Wimett, Gary Laustsen. Duloxetine fights major depressive disorder[J]. Nurse Pract, 2005;30(3):6-7.
10Corcoran C, Wong ML, O' Keane V. Bupropion in the management of apathy[J]. Psychopharmacol, 2004; 18(1 ): 133-135.
